Drug evaluation: K-111, an insulin-sensitizing peroxisome proliferator-activated receptor alpha agonist.
Kozva Co Ltd, under license from Roche Holding AG, is developing K-111, an orally available peroxisome proliferator-activated receptor a ligand and insulin-potentiating agent, for the potential treatment of type 2 diabetes. Phase II clinical trials of K-111 are underway.
Drew
Brian G
BG
Baker Heart Research Institute, Juvenile Diabetes Research Foundation Centre for Diabetes Complications, PO Box 6492, St Kilda Road Central, Melbourne 8008, Australia.
Calkin
Anna C
AC
D000818:Animals; D017322:Clinical Trials, Phase II as Topic; D003924:Diabetes Mellitus, Type 2 / Q000188:drug therapy; D004341:Drug Evaluation / Q000379:methods*; D004353:Drug Evaluation, Preclinical / Q000379:methods; D006801:Humans; D007004:Hypoglycemic Agents / Q000494:pharmacology / Q000627:therapeutic use; D007328:Insulin / Q000494:pharmacology / Q000627:therapeutic use*; D007850:Lauric Acids / Q000494:pharmacology / Q000627:therapeutic use*; D047493:PPAR alpha / Q000819:agonists*
C116893:2,2-dichloro-12-(p-chlorophenyl)-dodecanoic acid; D007004:Hypoglycemic Agents; D007328:Insulin; D007850:Lauric Acids; D047493:PPAR alpha